Starpharma Holdings Limited (SPL), listed on the Australian Securities Exchange (ASX), is a biopharmaceutical company at the forefront of dendrimer technology for medical applications. Leveraging this innovative platform, Starpharma is focused on developing and commercializing novel therapeutic products that address unmet needs in global healthcare. The company's dedication lies in translating cutting-edge science into tangible solutions that improve patient outcomes and quality of life.